Human Liver Kept Viable Outside Body for Record Seven Weeks
Australian researchers sustain a donated liver ex vivo for 47 days, signaling a shift toward semi-elective transplants and advanced bioengineering repair.

EXECUTIVE BRIEF // KEY TAKEAWAYS
Australian researchers sustain a donated liver ex vivo for 47 days, signaling a shift toward semi-elective transplants and advanced bioengineering repair.
SYDNEY — A biomedical research team in Australia has maintained a donated human liver in a functioning, viable state outside the body for a record-breaking seven weeks, according to a report published by MIT Technology Review. The achievement, carried out in Sydney by a team led by transplant surgeon and inventor Carlo Pulitano, more than triples previous international benchmarks for ex vivo organ preservation and challenges foundational biological limits that have governed organ viability for more than half a century.
The sustained ex vivo preservation represents an inflection point for clinical supply chains, healthcare economics, and biotechnology development. If confirmed in forthcoming peer-reviewed studies, expanding organ viability from a precarious window of hours to nearly two months will dismantle the emergency logistical bottlenecks that dictate modern transplant surgery. Beyond eliminating the crisis-driven midnight operations and severe geographic transit radii that currently limit patient access, the capability creates an extended therapeutic runway to evaluate, repair, and bioengineer marginal organs outside the human body.
Clinical Context and the Limitations of Cold Storage
For decades, solid-organ transplantation has remained dependent on static cold storage, a rudimentary preservation protocol in which harvested organs are flushed with preservation fluid and submerged on ice at temperatures between 0 and 4 degrees Celsius. Although hypothermia slows cellular metabolism and delays ischemic damage, cellular degradation inevitably accelerates within hours. In clinical practice, the viable threshold for a retrieved human liver rarely exceeds 8 to 12 hours, forcing hospital procurement networks to reject thousands of donor organs each year due to transit delays or minor tissue damage.
The Sydney research initiative sought to overcome these physiological constraints by deploying normothermic machine perfusion, a technique that maintains donor tissue at normal physiological body temperature of approximately 37 degrees Celsius. Rather than inducing metabolic arrest on ice, the apparatus supplies the organ with oxygenated blood, specialized nutritional infusions, and automated continuous waste removal.
According to MIT Technology Review, Pulitano and his colleagues connected the donated human liver to an advanced artificial life-support apparatus designed to replicate human circulatory, respiratory, and metabolic functions outside the body.
“Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering,” MIT Technology Review reported, noting that complete technical details of the breakthrough remain pending publication.
The 47-day survival span surpasses the previous record established by a Swiss research consortium, which successfully preserved a compromised human liver ex vivo for up to two weeks on a mechanized circuit before transplanting the repaired organ into a patient.
Operational Economics and Technological Transformation
Extending preservation windows to seven weeks carries transformative operational implications for global hospital systems. Current procurement operations rely heavily on rapid-response charter aviation, dedicated couriers, and on-call surgical squads mobilized at all hours of the night. Transitioning organ transplantation into planned, semi-elective daytime procedures promises to curtail hospital overtime costs, reduce staffing fatigue, and stabilize medical resource utilization.
The economic stakes are particularly acute given the persistent mismatch between donor organ supply and patient demand. In the United States alone, where more than 10,000 candidates remain on liver transplant waiting lists, federal registry data indicates that between 20 and 30 percent of retrieved donor livers are ultimately discarded because of macrosteatosis, donor age, or extended ischemic exposure. An extended multi-week perfusion window provides clinical teams with the operational runway required to perform automated organ defatting, administer targeted gene therapies, and deliver localized cellular interventions to rehabilitate discarded grafts prior to transplantation.
Beyond transplantation logistics, a reliable seven-week ex vivo organ model introduces a functional living platform for pharmacological development. Pharmaceutical companies and academic researchers could utilize functioning human livers to evaluate drug toxicity, metabolic processing, and novel biological formulations with higher fidelity than animal models, accelerating discovery pipelines while reducing human trial risks.
Strategic Outlook and Regulatory Hurdles
While the milestone demonstrates unprecedented physiological longevity, significant scientific and commercial hurdles precede widespread clinical deployment. The immediate milestone will be the release of peer-reviewed data, where independent clinical scientists will analyze cellular viability, metabolic clearance, and histological integrity throughout the 47-day run.
Subsequent regulatory hurdles will test whether livers maintained under prolonged extracorporeal support can tolerate reperfusion and function safely upon transplantation into human recipients. Regulatory authorities, including the U.S. Food and Drug Administration and the Australian Therapeutic Goods Administration, will require rigorous preclinical safety trials and randomized studies before approving closed-loop perfusion platforms for expanded preservation indications.
As specialized medical technology manufacturers and venture capital investors deploy capital into next-generation bioreactors and machine perfusion systems, the Australian breakthrough affirms that the temporal limits of organ viability are increasingly flexible. The paradigm of organ preservation is rapidly evolving from passive hypothermic storage toward active ex vivo rehabilitation and automated biological engineering.


